Tanja Obradovic, Therapeutic Strategy Lead of Oncology at Novotech, Senior Advisor of Oncology Drug Development at HopeAI, shared a post on LinkedIn:
“Major Advancement for Pancreatic Cancer Patients with Daraxonrasib
Almost Doubling Survival in RASmut Patients with Community Eagerly Awaiting Report at ASCO2026 and Mounting Pressure on Early Access Program (EAP).
Outstanding advancement for patients with RASmut pancreatic ductal adenocarcinoma (PDAC) who progressed on prior therapy who can already have early access to Daraxonrasib. As of May 2026, the FDA has authorized an Expanded Access Program (EAP) for Daraxonrasib (RMC-6236), a RAS(ON) multiselective inhibitor from Revolution Medicines. This program offers early, free-of-charge access to the drug for eligible patients with previously treated metastatic pancreatic ductal adenocarcinoma (PDAC) who have no other options.
Patients and centers around US are reacting fast including outstanding pancreatic patient advocacy of The Pancreatic Cancer Action Network who has provided link to program information for patients.
Revolution Medicines will present pivotal Phase III RASolute 302 trial results for Daraxonrasib in previously treated metastatic pancreatic cancer (PDAC) at the ASCO 2026 Annual (Plenary Session on May 31, at 3:21–3:33). The study met its primary endpoints, showing a significant survival benefit with a median overall survival (OS) of 13.2 months vs. 6.7 months for chemotherapy (HR 0.40). Full publication of findings from phase 1/2 trial that served as support for RASolute 302 trial has just been published in the New England Journal of Medicine.
Considering that over 90% of PDAC patients carry RASmut benefit will be for many and there are already reports of extreme demand from cancer centers around US for early Daraxonrasib while rapid reaction from FDA is awaited. Truly great accomplishment of Revolution Medicines team and commitment to patients.”